ROBOTIC
VITESTRO ACHIEVES CE MARKING FOR AUTONOMOUS BLOOD DRAWING DEVICE
The CE marking underscores the safety , efficacy and quality of Vitestro ’ s innovative technology , which is set to revolutionise the way blood samples are collected . Through a combination of advanced imaging technology and robotics , the device enables hospitals and labs to provide accurate autonomous blood draws , reducing the need for manual handling and improving patient and clinician satisfaction . Vitestro has managed to automate the missing step in total lab automation . This is critical as clinical laboratories are experiencing a severe staffing shortage .
Co-founder and CEO , Toon Overbeeke , expressed his enthusiasm about the achievement : “ While this CE marking represents a major step forward for Vitestro , it also marks a transformational moment for healthcare at large . This innovation introduces a completely novel type of medical device – one that allows European hospitals to use autonomous technology to perform invasive medical procedures independently . We believe this technology is foundational , setting a new global standard that will benefit patients and help hospitals prepare for a challenging future .”
Several devices have already been ordered by leading European hospitals and clinical laboratories . With the CE marking secured , Vitestro plans a limited market release at these selected hospitals in the next 12 months . Production will be scaled up afterwards , adhering to Vitestro ’ s demonstrated Quality Assurance processes .
Maxine Moor , VP of Commercial Europe , added : “ Vitestro has
been interacting with clinical labs throughout Europe for the past years . They confirmed the huge need for phlebotomy automation and couldn ’ t wait for this innovation ! We are eager to start the implementation of our devices in hospitals and laboratories in the coming 12 months . While we will start within the Netherlands and Denmark , we have huge , broader international ambitions . With the CE mark , we are also meeting regulatory demands for the UK market .” �
56 www . intelligenthealth . tech